Marshall Wace
VNDA icon

Marshall Wace’s Vanda Pharmaceuticals VNDA Stock Holding History

Marshall Wace’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.12M Buy
+596,002
New +$4.6M ﹤0.01% 1393
2025
Q4 		– Sell
-581,247
Closed -$2.9M – 3516
2025
Q3 		$2.9M Buy
581,247
+109,527
+23% +$507K ﹤0.01% 1434
2025
Q2 		$2.23M Buy
471,720
+426,620
+946% +$1.87M ﹤0.01% 1504
2025
Q1 		$207K Sell
45,100
-35,700
-44% -$166K ﹤0.01% 2391
2024
Q4 		$387K Buy
+80,800
New +$388K ﹤0.01% 2138
2024
Q3 		– Sell
-24,504
Closed -$138K – 2988
2024
Q2 		$138K Sell
24,504
-42,141
-63% -$218K ﹤0.01% 2363
2024
Q1 		$274K Sell
66,645
-120,852
-64% -$484K ﹤0.01% 2141
2023
Q4 		$791K Buy
+187,497
New +$757K ﹤0.01% 1558
2022
Q3 		– Sell
-12,818
Closed -$140K – 3828
2022
Q2 		$140K Sell
12,818
-3,846
-23% -$39.9K ﹤0.01% 3230
2022
Q1 		$189K Buy
+16,664
New +$219K ﹤0.01% 3117
2021
Q1 		– Sell
-121,010
Closed -$1.59M – 2888
2020
Q4 		$1.59M Sell
121,010
-153,844
-56% -$1.85M 0.01% 1043
2020
Q3 		$2.65M Buy
274,854
+174,061
+173% +$1.86M 0.02% 726
2020
Q2 		$1.15M Sell
100,793
-546,667
-84% -$6.19M 0.01% 957
2020
Q1 		$6.71M Buy
647,460
+185,769
+40% +$2.3M 0.07% 299
2019
Q4 		$7.58M Buy
461,691
+4,546
+1% +$68.7K 0.05% 384
2019
Q3 		$6.07M Buy
457,145
+405,975
+793% +$5.66M 0.05% 446
2019
Q2 		$721K Buy
51,170
+51,156
+365,400% +$814K 0.01% 1007
2019
Q1 		$0 Buy
+14
New +$319 ﹤0.01% 2079
2018
Q4 		– Sell
-86,835
Closed -$1.99M – 1825
2018
Q3 		$1.99M Buy
+86,835
New +$1.77M 0.02% 681
2015
Q3 		– Sell
-59,233
Closed -$752K – 1072
2015
Q2 		$752K Buy
59,233
+46,209
+355% +$498K 0.01% 649
2015
Q1 		$121K Buy
+13,024
New +$147K ﹤0.01% 767
2014
Q2 		– Sell
-170,104
Closed -$2.76M – 1072
2014
Q1 		$2.76M Buy
+170,104
New +$2.42M 0.05% 308

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's VNDA Position: Q1 2026 in Review

Marshall Wace opened a new position in Vanda Pharmaceuticals (VNDA) in Q1 2026: 596,002 shares worth $4.12M. The stake represents ﹤0.01% of the portfolio and ranks #1393 among its holdings. This is a return to the name: Marshall Wace previously reported a position in VNDA as recently as Q3 2025.

Marshall Wace first reported a position in VNDA in Q1 2014 and has held it in 22 quarters since. The position peaked at $7.58M in Q4 2019. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Marshall Wace held 596,002 shares of Vanda Pharmaceuticals worth $4.12M as of Q1 2026.
  • Vanda Pharmaceuticals was a new Marshall Wace position in Q1 2026.
  • Vanda Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1393 holding.
  • Marshall Wace first reported a position in Vanda Pharmaceuticals in Q1 2014 and has held it in 22 quarters since.
  • Marshall Wace's Vanda Pharmaceuticals position peaked at $7.58M in Q4 2019.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.